BidaskClub upgraded shares of Simulations Plus (NASDAQ:SLP) from a buy rating to a strong-buy rating in a report issued on Wednesday morning.
Other equities analysts also recently issued reports about the company. Zacks Investment Research cut shares of Simulations Plus from a buy rating to a hold rating in a report on Friday, March 23rd. ValuEngine raised shares of Simulations Plus from a hold rating to a buy rating in a report on Monday, April 2nd.
Simulations Plus opened at $21.30 on Wednesday, MarketBeat reports. The stock has a market capitalization of $363.85 million, a P/E ratio of 62.65 and a beta of -0.54. Simulations Plus has a one year low of $11.80 and a one year high of $21.45.
Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Monday, April 9th. The technology company reported $0.11 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.11. The business had revenue of $7.36 million during the quarter, compared to the consensus estimate of $7.37 million. Simulations Plus had a return on equity of 26.19% and a net margin of 30.65%. analysts anticipate that Simulations Plus will post 0.4 EPS for the current fiscal year.
In other Simulations Plus news, Chairman Walter S. Woltosz sold 18,500 shares of the firm’s stock in a transaction dated Tuesday, March 27th. The shares were sold at an average price of $14.54, for a total value of $268,990.00. Following the transaction, the chairman now owns 5,466,408 shares of the company’s stock, valued at $79,481,572.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO John Robert Kneisel sold 2,991 shares of the firm’s stock in a transaction dated Friday, April 20th. The stock was sold at an average price of $17.64, for a total transaction of $52,761.24. The disclosure for this sale can be found here. Insiders sold 58,491 shares of company stock worth $996,446 in the last three months. 33.45% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its holdings in shares of Simulations Plus by 142.2% during the fourth quarter. The Manufacturers Life Insurance Company now owns 9,378 shares of the technology company’s stock valued at $151,000 after buying an additional 5,506 shares during the last quarter. Bank of Montreal Can bought a new stake in shares of Simulations Plus during the fourth quarter valued at approximately $104,000. Renaissance Technologies LLC raised its holdings in shares of Simulations Plus by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 525,100 shares of the technology company’s stock valued at $8,454,000 after buying an additional 14,100 shares during the last quarter. Santa Monica Partners LP bought a new stake in shares of Simulations Plus during the fourth quarter valued at approximately $532,000. Finally, Martingale Asset Management L P raised its holdings in shares of Simulations Plus by 6.5% during the fourth quarter. Martingale Asset Management L P now owns 69,107 shares of the technology company’s stock valued at $1,113,000 after buying an additional 4,201 shares during the last quarter. 35.13% of the stock is currently owned by hedge funds and other institutional investors.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.